What are cookies?
A cookie is a small file containing a string of characters that is sent to your computer when you visit a website. When you visit the site again, the cookie allows that site to recognise your browser. This way, the information you previously provided can be retrieved. Cookies may store user preferences and other information to enhance your experience on the site or be used to track you when you navigate to other sites.
What types of cookies are used on this site?
Strictly necessary cookies: These cookies are necessary to make the site work properly.
Analytics cookies: These cookies collect information that is used to help us understand how the site is being used.
What cookies are used on this site?
This cookie is used to keep the context of a visitor (e.g. to keep you logged in on the site).
This cookie is used to identify the web link used to direct visitors to the site.
This cookie is used to hide the cookie banner once you have interacted with it.
This cookie is used to gather insights about how visitors use the site.
Your control of cookies
You have the right to decide whether to accept or reject cookies that are not strictly necessary. You can do so by:
Indicating your preference on the banner that appears when you enter the site.
Clicking “Cookie Preferences” on the banner that appears when you enter the site, to tailor your preferences.
Changing your already selected preferences by clicking the link “Manage Cookies”, which is always available at the bottom of the site.
Restricting cookies by altering your browser settings. The way in which you can restrict cookies varies from browser to browser. You should therefore visit your web browser's help menu for more information.
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.